SCHEMBL6950817

SCHEMBL6950817

Cc1nc(N2CCc3ccc(F)cc3CC2)c([N+](=O)[O-])c(=O)[nH]1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TYMS P04818 2/20 0.44
RAB9A P51151 2/20 0.40
NR3C2 P08235 1/20 0.38
POLB P06746 2/20 0.36
MAPK1 P28482 1/20 0.36
MEN1 O00255 1/20 0.35
GFER P55789 1/20 0.35
KMT2A Q03164 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.34
MAPT P10636 4/20 0.34
HTT P42858 3/20 0.34
CYP1A2 P05177 2/20 0.33
CYP2C9 P11712 2/20 0.33
CYP2C19 P33261 2/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2D6 P10635 1/20 0.33
JAK2 O60674 1/20 0.33
JAK1 P23458 1/20 0.33
TYK2 P29597 1/20 0.33
JAK3 P52333 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6955056 0.88 PNMT (0.40) TYMSMAPK1MEN1KMT2ASMN1; SMN2
SCHEMBL6953047 0.87 MAPT (0.38) RAB9AMAPK1MEN1KMT2ASMN1; SMN2
SCHEMBL6947740 0.87 TYMS (0.44) TYMSPOLBMEN1GFERKMT2A
SCHEMBL6951360 0.85 LMNA (0.42) RAB9AMEN1KMT2ASMN1; SMN2MAPT
SCHEMBL6948442 0.84 CA1 (0.41) MAPK1KMT2ASMN1; SMN2MAPTHTT
SCHEMBL6952830 0.82 RAB9A (0.47) RAB9APOLBMAPK1MEN1KMT2A
SCHEMBL4417030 0.81 POLB (0.51) POLBMAPK1MEN1KMT2ASMN1; SMN2
SCHEMBL6955100 0.81 MAPT (0.39) MAPK1KMT2ASMN1; SMN2MAPTHTT
SCHEMBL6950705 0.79 MAPT (0.40) RAB9ANR3C2POLBMAPK1MEN1
SCHEMBL6435436 0.79 MAPT (0.35) RAB9APOLBMAPK1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1074549-B1 Tetrahydro-benzo(d)azepines and their use as antagonists at metabotropic glutamate receptors HOFFMANN LA ROCHE (CH) 2003-11-19 EP disclosed
US-6218385-B1 FOR THERAPY OR PROPHYLAXIS OF ACUTE AND/OR CHRONIC NEUROLOGICAL DISORDERS SUCH AS EPILEPSY, STROKE, CHRONIC AND ACUTE PAIN, PSYCHOSIS, SCHIZOPHRENIA, ALZHEIMER'S DISEASE, COGNITIVE DISORDERS AND MEMORY DEFICITS HOFFMANN-LA ROCHE INC. 2001-04-17 US disclosed
EP-1074549-A2 Tetrahydro-benzo(d)azepines and their use as antagonists at metabotropic glutamate receptors F. HOFFMANN-LA ROCHE AG (CH) 2001-02-07 EP disclosed